
- /
- Supported exchanges
- / US
- / JANX.NASDAQ
Janux Therapeutics Inc (JANX NASDAQ) stock market data APIs
Janux Therapeutics Inc Financial Data Overview
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Janux Therapeutics Inc data using free add-ons & libraries
Get Janux Therapeutics Inc Fundamental Data
Janux Therapeutics Inc Fundamental data includes:
- Net Revenue: 9 336 K
- EBITDA: -111 536 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-28
- EPS/Forecast: -0.4533
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Janux Therapeutics Inc News

Janux Therapeutics Becomes Oversold (JANX)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a te...


Janux Therapeutics reports annual meeting results
On June 11, 2025, Janux Therapeutics, Inc., a biotechnology company currently valued at $1.48 billion, conducted its 2025 Annual Meeting of Stockholders. The meeting occurred amid challenging market c...

SA Asks: Which oncology companies are attractive M&A targets?
[word m and a made with wood building blocks, stock image] Maksim Labkouski Which cancer drug developers are attractive takeover targets? We asked Seeking Alpha analysts BioCGT Investor [https://see...

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer
Ms. Doyle brings more than two decades of corporate strategy and business development experience across biotech, pharma, and venture ecosystems SAN DIEGO, May 15, 2025--(BUSINESS WIRE)--Janux Therape...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.